Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma

References

• Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386–2395
   PubMed Web of Science ®Google Scholar
• Aleman B M, van den Belt-Dusebout A W, Klokman W J, Van't Veer M B, Bartelink H, van Leeuwen F E. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431–3439
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• Josting A, Franklin J, May M, Koch P, Beykirch M K, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20: 221–230
   PubMed Web of Science ®Google Scholar
• Re D, Thomas R K, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005; 105: 4553–4560
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J, Tosato G, Jaffe E S. The role of chemokines in Hodgkin's disease. Leuk Lymphoma 2000; 38: 363–371
   PubMed Web of Science ®Google Scholar
• Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002; 13(Suppl 1)52–56
   PubMed Web of Science ®Google Scholar
• Casasnovas R O, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 1732–1740
   PubMed Web of Science ®Google Scholar
• Diehl V, Engert A, Re D. New strategies for the treatment of advanced-stage Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007; 21: 897–914
   PubMed Web of Science ®Google Scholar
• Pogge van Strandmann E, Simhadri V R, Tresckow B V, Sasse S, Reiners K S, Hansen H P, et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007;2:965–974
   Web of Science ®Google Scholar
• Marshall N A, Christie L E, Munro L R, Culligan D J, Johnston P W, Barker R N, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755–1762
   PubMed Web of Science ®Google Scholar
• Juszczynski P, Ouyang J, Monti S, Rodig S J, Takeyama K, Abramson J, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007; 104: 13134–13139
   PubMed Web of Science ®Google Scholar
• Herbst H, Foss H D, Samol J, Araujo I, Klotzbach H, Krause H, et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996; 87: 2918–2929
   PubMed Web of Science ®Google Scholar
• Herbst H. Epstein-Barr virus in Hodgkin's disease. Semin Cancer Biol 1996; 7: 183–189
   PubMed Web of Science ®Google Scholar
• Gandhi M K, Tellam J T, Khanna R. Epstein-Barr virus-associated Hodgkin's lymphoma. Br J Haematol 2004; 125: 267–281
   PubMed Web of Science ®Google Scholar
• Gandhi M K, Lambley E, Burrows J, Dua U, Elliott S, Shaw P J, et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 460–464
   PubMed Web of Science ®Google Scholar
• Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol 2000; 79: 110–113
   PubMed Web of Science ®Google Scholar
• Sarris A H, Kliche K O, Pethambaram P, Preti A, Tucker S, Jackow C, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999; 10: 433–440
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos T P, Nadali G, Angelopoulou M K, Siakantaris M P, Dimopoulou M N, Kontopidou F N, et al. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica 2001; 86: 274–281
   PubMed Web of Science ®Google Scholar
• Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998; 91: 3011–3016
   PubMed Web of Science ®Google Scholar
• Weihrauch M R, Manzke O, Beyer M, Haverkamp H, Diehl V, Bohlen H, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 2005; 65: 5516–5519
   PubMed Web of Science ®Google Scholar
• Fischer M, Bijman M, Molin D, Cormont F, Uyttenhove C, van Snick J, et al. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia 2003; 17: 2513–2516
   PubMed Web of Science ®Google Scholar
• Skinnider B F, Kapp U, Mak T W. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 2002; 43: 1203–1210
   PubMed Web of Science ®Google Scholar
• Jundt F, Anagnostopoulos I, Bommert K, Emmerich F, Muller G, Foss H D, et al. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999; 94: 2065–2071
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008;22:769–776
   PubMed Web of Science ®Google Scholar
• Buri C, Korner M, Scharli P, Cefai D, Uguccioni M, Mueller C, et al. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease. Blood 2001; 97: 1543–1548
   PubMed Web of Science ®Google Scholar
• Passam F H, Alexandrakis M G, Moschandrea J, Sfiridaki A, Roussou P A, Siafakas N M. Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis. Int J Immunopathol Pharmacol 2006; 19: 161–170
   PubMed Web of Science ®Google Scholar
• Giles F J, Vose J M, Do K A, Johnson M M, Manshouri T, Bociek G, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 2004; 28: 595–604
   PubMed Web of Science ®Google Scholar
• Chiu A, Xu W, He B, Dillon S R, Gross J A, Sievers E, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007; 109: 729–739
   PubMed Web of Science ®Google Scholar
• Munro L R, Johnston P W, Marshall N A, Canning S J, Hewitt S G, Tveita K, et al. Polymorphisms in the interleukin-10 and interferon gamma genes in Hodgkin lymphoma. Leuk Lymphoma 2003; 44: 2083–2088
   PubMed Web of Science ®Google Scholar
• Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 2007; 18: 1376–1381
   PubMed Web of Science ®Google Scholar